HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
JSPR
Jasper Therapeutics, Inc.
There isn't enough reported data to score JSPR yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
JSPR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
JSPR's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
JSPR PE Valuation
JSPR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
JSPR Forward outlook
There aren't enough analyst estimates for JSPR to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
JSPR has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus JSPR down 226%.
JSPR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$177.90 | -$36.31 |
| Q2 2025 | -$181.20 | -$28.81 |
| Q1 2025 | -$158.10 | +$10.19 |
| Q4 2024 | -$146.70 | +$38.69 |
| Q3 2024 | -$141.59 | +$112.75 |
| Q2 2024 | -$152.39 | +$149.95 |
| Q1 2024 | -$168.29 | +$171.23 |
| Q4 2023 | -$185.39 | +$123.61 |
JSPR is still losing money, but less than at its worst: $177.90 per share over the past year, against $339.52 at its worst in early 2023.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
JSPR Quarterly Revenue
JSPR and HIMS do not have enough comparable growth data to identify a winner.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
JSPR has the stronger cash trend. Its trailing FCF is down 20% versus its history, compared with HIMS at down 84%.
JSPR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$14.5M | +$8.3M |
| Q4 2025 | -$21.9M | -$733K |
| Q3 2025 | -$17M | -$2.9M |
| Q2 2025 | -$15.5M | -$3.8M |
| Q1 2025 | -$22.8M | -$7.1M |
| Q4 2024 | -$21.1M | -$4.7M |
| Q3 2024 | -$14.1M | -$2.1M |
| Q2 2024 | -$11.7M | +$1.6M |
JSPR has burned cash in almost every quarter: −$69M over the past year, against −$70M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over JSPR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
JSPR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +838 shares |
| 1 year | +91% | +456K shares |
| 3 years | +226% | +663K shares |
JSPR has 956,565 diluted shares, up 91% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
JSPR Net Leverage
JSPR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
JSPR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 13.5 | Oversold |
JSPR's weekly RSI is 36 (neutral) and its Stochastic is 14 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
JSPR PE vs Healthcare Sector
JSPR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
JSPR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.0 | 16% below |
| 20 week MA | $18.6 | 28% below |
| 50 week MA | $28.2 | 53% below |
| 100 week MA | $90.9 | 85% below |
| 200 week MA | $296.8 | 95% below |
JSPR is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over JSPR on returns for 2026, with the stronger performance.
JSPR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2,946.0 | $3,027.0 | +2.7% |
| 2021 | $3,027.0 | $2,784.0 | -8% |
| 2022 | $2,784.0 | $166.2 | -94% |
| 2023 | $166.2 | $236.7 | +42% |
| 2024 | $236.7 | $667.5 | +182% |
| 2025 | $667.5 | $52.8 | -92% |
| 2026 YTD | $52.8 | $13.4 | -75% |
JSPR's yearly returns have swung widely, from +182% in 2024 to −94% in 2022. It's down 75% so far in 2026.